Ownership

Providence Therapeutics Announces New Board Appointment

Retrieved on: 
Thursday, October 28, 2021
RNA transfection, Ionis Pharmaceuticals, Biology, University, Biochemistry, Vaccine, IP, United States Court of Appeals for the Federal Circuit, Alnylam Pharmaceuticals, COVID19, RNA interference, Thomas Jefferson School of Law, Clinical trial, RNA, Federal Circuit Bar Journal, Doctor of Philosophy, University of Kentucky College of Medicine, Commonwealth, Patent, United States Patent and Trademark Office, Board, CEO, COVID-19, Growth, Thomas Jefferson School (St. Louis, Missouri), AB, Cumberland University, Therapy, Ownership, PC, Gene editing, Board of directors, Management, Pharmaceutical industry

appointment to Board of Directors.

Key Points: 
  • appointment to Board of Directors.
  • Her work advising Providence on IP over the past five years has been exemplary, and as Providence enters a new phase of growth, having her input at a governance and strategic level is wonderful," says Brad Sorenson, CEO of Providence.
  • Providence is a leading Canadian clinical stage private biotechnology company pioneering mRNA therapeutics and vaccines with operations in Calgary, Alberta and Toronto, Ontario.
  • Providence is focused on serving the needs of Canada, and other countries that may be underserved by large pharmaceutical programs.

Robotaxis Will Be Disruptive to Conventional Taxis and Ride-Hailing, but Not Car Ownership

Retrieved on: 
Thursday, October 28, 2021
Safety, Lux, Research, Technology, Geography, Car, Economics, Robotaxi, Weather, SAE, Thought, Growth, Multimedia, Ownership, Satellite navigation device, Ridesharing company

Developers of autonomous vehicles, specifically those focused on level-4 self-driving vehicles, often focus on mobility services as the first application.

Key Points: 
  • Developers of autonomous vehicles, specifically those focused on level-4 self-driving vehicles, often focus on mobility services as the first application.
  • Lux's new report, "The Economics of Robotaxis," analyzes the economics of fleet ownership of autonomous vehicles for ride-hailing purposes, finding costs to use these services will likely exceed personal car ownership but be cheaper than conventional taxi or ride-hailing services.
  • "Robotaxis are currently in the pilot stage, with several operating today," says Christopher Robinson, Research Director at Lux Research and lead author of the report.
  • While robotaxi operations will be disruptive to incumbent ride-hailing companies due to the significantly more favorable economics, ultimately, robotaxis will not meaningfully displace car ownership due to higher costs and the social status ascribed to such ownership.

Wivity Unveils New Service to Secure NFTs

Retrieved on: 
Thursday, October 28, 2021
San Francisco Arts Commission, Technology, SAN, NFT, Wallace Foundation, Organization, Root, Chinese Culture Center, Color, CCC, CEO, Grant (money), Multimedia, Non-fungible token, Ownership, Education, Cryptocurrency, Online shopping

The service uses trusted third parties to verify the origins of an NFT, so artists can secure their work and collectors can trust the authenticity of their purchases.

Key Points: 
  • The service uses trusted third parties to verify the origins of an NFT, so artists can secure their work and collectors can trust the authenticity of their purchases.
  • "The long-term success of NFTs depends on accurate provenance the ability to verify who created the NFT and who owns it," says Alfred Tom, Co-founder and CEO of Wivity.
  • "We are excited to launch this service at CCC's first NFT auction and bring more trust to NFT marketplaces, collectors and the creators themselves."
  • Wivity's Root of Provenance service will help secure NFTs for both artists and collectors, and we are excited to be the first auction to leverage this ground-breaking NFT innovation."

Electric Last Mile Solutions Pioneers EV Campus Program as Universities Nationwide Seek a Zero Emissions Future

Retrieved on: 
Thursday, October 28, 2021
Efficiency, University, Goal, Industry, Carbon, Electricity, ELMS, Notre Dame, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, NASDAQ, ESG, EVS, EV, Â, Maintenance, Company, COVID-19, Growth, Solution, Nasdaq, GLOBE, Ownership, School, Satellite navigation device, Management, Risk management

The EV Campus Program will allow universities to pilot an ELMS Urban Delivery commercial electric vehicle free of charge for up to four weeks.

Key Points: 
  • The EV Campus Program will allow universities to pilot an ELMS Urban Delivery commercial electric vehicle free of charge for up to four weeks.
  • The university will utilize the vehicle within campus boundaries covering a wide range of use cases during the duration of the pilot.
  • This groundbreaking program is uniquely designed to serve colleges and universities seeking a green future, said Ron Feldeisen, Chief Revenue Officer, ELMS.
  • For colleges and universities aiming to reach their sustainability goals through the ELMS EV Campus Program, contact [email protected] .

Daymak to Auction First Spiritus Production Car Paired With Exclusive “Beyond the Black Diamond” NFT Artwork Chronicling the Creation of World’s First Crypto-Mining Electric Vehicle

Retrieved on: 
Thursday, October 28, 2021
Diamond, AC Cobra, Technology, Acceleration, Unit, Creativity, NFT, Daily Bread Food Bank, Lev Tikhomirov, Achievement, EV, Time, Collection, Blockchain, Company, Black Diamond, Walmart, Ferrari, Non-fungible token, Light electric vehicle, Magic, Black, GLOBE, Ownership, Sale, Mining, Cryptocurrency, Toy, Online shopping

This NFT is one pillar of the innovative strategy Daymak is utilizing to make its mark and achieve something few have.

Key Points: 
  • This NFT is one pillar of the innovative strategy Daymak is utilizing to make its mark and achieve something few have.
  • It has not been a smooth journey getting here, said Aldo Baiocchi, President of Daymak.
  • The completion of the Spiritus prototype is a massive milestone for us, and this NFT marks that achievement.
  • This ownership is a separate NFT, which will be transferred to the wallet of the winning bidder on Beyond the Black Diamond .

Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

Retrieved on: 
Thursday, October 28, 2021
Safety, Myelodysplastic syndrome, European Medicines Agency, Failure, Holding, COVID-19, Cholangiocarcinoma, CHAM, AML, GLOBE, Filgrastim, Cytarabine, TCA, FFX, Regulation of tobacco by the U.S. Food and Drug Administration, Survival, Etoposide, Mitoxantrone, RFL, Private Securities Litigation Reform Act, Food, HAM, Annual report, Company, Investment, Pancreatic cancer, Peripheral T-cell lymphoma, ECOG, EMA, NYSE, SEC, FOLFIRINOX, CEO, Pancreas, Public health, Phase 1, Patient, Cancer, MEC, International Cancer Genome Consortium, FDA, FLAG, Conference, Acute myeloid leukemia, Therapy, Ownership, Pharmaceutical industry

NEWARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), a holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. (“Rafael Pharmaceuticals”) as well as other investments in early-stage ventures, today announced that the AVENGER 500 Phase 3 clinical trial for CPI-613® (devimistat), Rafael Pharmaceuticals’ lead product candidate, did not meet its primary endpoint of significant improvement in overall survival in patients with metastatic adenocarcinoma of the pancreas.

Key Points: 
  • The median overall survival in the treatment arm was 11.1 months, compared to 11.7 months in the control arm.
  • Devimistat is also being evaluated in a multi-national Phase 3 randomized clinical trial, ARMADA 2000, in patients with relapsed or refractory acute myeloid leukemia (AML).
  • Following a pre-specified interim analysis, the independent data monitoring committee has recommended the trial be stopped due to lack of efficacy.
  • The European Medicines Agency (EMA) has granted orphan drug designation to devimistat for pancreatic cancer, acute myeloid leukemia and Burkitts lymphoma.

Abacus Provides Update on Willow Drilling

Retrieved on: 
Thursday, October 28, 2021
Hudbay Minerals, Copper, Anaconda, TSX Venture Exchange, KGHM, Environment, Climate change, Abacus, Geo-Mineral Exploration Corporation, COVID-19, National instrument, Engineering, MacArthur, SIOS Technology Corp., Molybdenum, Ajax, Forward-looking statement, Technical, Company, Nevada Copper Belt Railroad, National Instrument 43-101, First Nations, Board, Petroleum, Gold, Program, Technical report, News, Ownership, GLOBE, KGHM Polska Miedź, Uranium, Online gambling

VANCOUVER, British Columbia, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Abacus Mining & Exploration Corporation (Abacus or the Company) (TSXV: AME) wishes to provide an update on the Willow porphyry copper drilling program in the Yerington copper camp, southeast of Reno, Nevada.

Key Points: 
  • VANCOUVER, British Columbia, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Abacus Mining & Exploration Corporation (Abacus or the Company) (TSXV: AME) wishes to provide an update on the Willow porphyry copper drilling program in the Yerington copper camp, southeast of Reno, Nevada.
  • Abacus completed geological, geochemical and geophysical work on Willow beginning in 2017 and then undertook a short core drilling program.
  • This drilling identified the Luhr Hill Granite on Willow with copper values in the 0.1% to 0.2% Cu range along with elevated Mo.
  • *
    Abacus has the right to earn a 75% ownership interest in the Willow property from Almadex America Inc, a wholly owned subsidiary of Almadex Minerals Ltd.

Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights

Retrieved on: 
Thursday, October 28, 2021
Safety, Gene, Disease, Failure, Degenerative disease, Spinal cord, EAE, Multiple sclerosis, Interim, Atopic dermatitis, Marketing, Clinical trial, Trial of the century, COVID-19, Inflammation, IND, GLOBE, Incidence, Research, Private Securities Litigation Reform Act, Part, Food, ID, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Confidentiality, Hospital, Robert Wood Johnson Medical School, Administration, Rutgers University, Veillonella parvula, Psoriasis Area and Severity Index, SEC, Growth, Letter, European Committee on Antimicrobial Susceptibility Testing, Cancer, Patient, Psoriasis, FDA, Investor, Neuroinflammation, MS, Board, Development, Ownership, Director, Treatment, Medical imaging, Pharmaceutical industry, Medical device, Vaccine, Frankincense

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today reported financial results and business highlights for the third quarter 2021.

Key Points: 
  • ET
    CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today reported financial results and business highlights for the third quarter 2021.
  • In September 2021, Evelo announced positive data from its Phase 2 clinical trial evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis.
  • In September 2021, Evelo announced the appointment of Professor Iain McInnes, M.B.Ch.B, Ph.D., to the Board of Directors.
  • In September 2021, Evelo announced the issuance of a U.S. composition of matter patent for pharmaceutical compositions comprising Veillonella parvula bacteria, including EDP1867.

Nexstar Media Group Declares Quarterly Cash Dividend of $0.70 Per Share

Retrieved on: 
Thursday, October 28, 2021
Marketing, Advertising, Communications, Other Consumer, Consumer, Technology, Audio, Video, Digital, Antenna TV, NewsNation, Industry, UHF, WGN (AM), Security (finance), U.S. Securities and Exchange Commission, CW, Private Securities Litigation Reform Act, NASDAQ, ABC, Nexstar Media Group, ABC Digital Network Division, Director, Achievement, Television, Nexstar, Communication, Rewind (TV channel), Forward-looking statement, Company, Board, Radio, NBC, Food Network, News, FOX, Broadcasting, CBS, Ownership, NXST, Media Group, Network, MyNetworkTV, Board of directors, Holding company

Nexstar Media Group, Inc. (NASDAQ: NXST) announced today that its Board of Directors declared a quarterly cash dividend of $0.70 per share of its Class A common stock.

Key Points: 
  • Nexstar Media Group, Inc. (NASDAQ: NXST) announced today that its Board of Directors declared a quarterly cash dividend of $0.70 per share of its Class A common stock.
  • While the Company intends to pay regular quarterly cash dividends for the foreseeable future, all subsequent dividends will be reviewed quarterly and declared by the Board of Directors at its discretion.
  • Nexstar Media Group, Inc. (NASDAQ: NXST) is a leading diversified media company that leverages localism to bring new services and value to consumers and advertisers through its traditional media, digital and mobile media platforms.
  • Its wholly owned operating subsidiary, Nexstar Media Inc., consists of three divisions: Broadcasting, Digital, and Networks.

ByHeart Has Become the First and Only Infant Formula in the US to Receive Clean Label Project Certification

Retrieved on: 
Thursday, October 28, 2021
Safety, Science, Breast milk, Pesticide, Quality, Research, SVP, Infant formula, Certification, Infant, World Health Organization, FDA, World, Trust, Life, Brain, Food, Growth, News, Health, Immune system, Ownership, Parent, Pharmaceutical industry, Toy

"Infant formula is the exclusive form of nourishment for so many babies during this significant period of brain and immune system development.

Key Points: 
  • "Infant formula is the exclusive form of nourishment for so many babies during this significant period of brain and immune system development.
  • With the addition of ByHeart infant formula to Clean Label Project's growing list of certified products, Clean Label Project's certification footprint now covers birth through adulthood in the US, establishing a foundation for long-term health.
  • ByHeart's commitment to Clean Label Project Purity Award certification is a testament to their commitment to nutrition and supply chain purity and quality."
  • The Clean Label Project screened ByHeart's formula for over 500 contaminants, including industrial and environmental toxins.